Use of spiperone derivatives as immunosuppressant agents

Details Use of spiperone derivatives as immunosuppressant agents Use of spiperone derivatives as immunosuppressant agents

1992-06-04

1996-11-12

Robinson, Allen J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514885, A61K 31445, A61K 31415

Patent

active

055740413

ABSTRACT:
A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

REFERENCES:
patent: 2788309 (1957-04-01), Cooper et al.
patent: 2854380 (1958-09-01), Jensen et al.
patent: 3155670 (1964-11-01), Janssen et al.
patent: 3238216 (1966-03-01), Janssen
patent: 3922266 (1975-11-01), Katsube et al.
patent: 3996363 (1976-12-01), Wade et al.
patent: 4228287 (1980-10-01), van der Stelt
patent: 4555504 (1985-11-01), Jones
patent: 4665075 (1987-05-01), Vandenberk et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 4874766 (1989-10-01), Ooms et al.
patent: 4937249 (1990-06-01), Antoku et al.
patent: 5137894 (1992-08-01), New et al.
patent: 5244902 (1993-09-01), Sharpe et al.
patent: 5290783 (1994-03-01), Sharpe et al.
Akamatsu, et al., "J. Investigative Dermatology." vol. 95, pp. 271-274 (1990).
Ameisen, et al., "A New Interpretation of The Involvement of Serotonin in Delayed-Type Hypersensitivity" The Journal of Immunology vol. 142 (9), pp. 3171-3179 (1989).
Blozovski, et al., "Action de la S erotonine de la R eserpine et D'Autres Agents Pharmacologiques sur la S ecr etion Sudorale. Etudes Hygrophotographiques" Arch. Int. Pharmacodyn. vol. 123, pp. 58-66 (1959).
"Chemical Abstracts" vol. 54, Abstract 215049-1.
Burka, et al., "Dopaminergic (Co-Mediator) Modulation of Release of Histamine and SRS-A in the Calf." British Journal of Pharmacology vol. 58 (3), p. 445 (1976).
Coffman, "The Attenuation by Reserpine or Guanethidine of the Cutaneous Vasoconstriction Caused by Tobacco Smoking", American Heart Journal vol. 74 (2), pp. 229-234 (1967) Chemical Abstracts vol. 67, p. 7624 81019W (1967).
Diezel, et al., "Inhibition of Cutaneous Contact Hypersensitivity by Calcium Transport Inhibitors Lanthanum and Diltiazem" The Journal for Investigative Dermatology vol. 93, pp. 322-325 (1989).
Eyre, "Dopamine Potentiates Anaphylactic Contraction of Pulmonary Vein of Calf." Research Communication in Chemical Pathology and Pharmacology vol. 22(3) pp. 447-453 (1978).
Fanta, "Calcium-Channel Blockers in Prophylaxis and Treatment of Asthma" The American Journal of Cardiology vol. 55, pp. 202B-209B (1985).
Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity" The Journal of Immunology vol. 139 (3), pp. 869-875 (1987).
Kligman, "The Comparitive Histopathology of Male-Pattern Baldness and Senescent Baldness" Clinics In Dermatology. pp. 108-118 (Oct. 1988).
Leysen, et al., "Receptor Binding of R 41 468, A Novel Antagonist at 5-HT.sub.2 Receptors." Life Sciences vol. 28(9), pp. 1015-1022 (1981).
Loffman, et al., "American Heart Journal" vol. 74(2), pp. 229-234, (1967).
"Chemical Abstracts" vol. 67, (1967), Abstract 81019W.
Login, et al., "Reserpine is a Calcium Channel Antagonist in Normal and GH.sub.3 Rat Pituitary Cells" American Journal of Physiology vol. 248, pp. E15-E19 (Jan. 1985).
Moerlein, et al., "Effect of Lipophilicity on the In Vivo Localization of Radiolabelled Spiperone Analogues", Int. J. Nucl. Med. Biol, vol. 12, No. 5, pp. 353-356 (1985).
Mekori, et al., "Studies of the Role of Mast Cells in Contact Sensitivity Responses Passive Transfer of the Reaction into Mast Cell-Deficient Mice Locally Reconstituted with Cultured Mast Cells: Effect of Reserpine on Transfer of the Reaction with DNP-Specific Cloned T Cells" Cellular Immunology vol. 109, pp. 39-52 (1987).
Nakanishi, et al., "Spirohydantoin Derivatives", Chemical Abstracts, Vo. 75, p. 437 (1971), Abstract 110315n.
Schroeder, et al., "Transient Absence of C5a-Specific Neutrophil Function in Inflammatory Disorders of the Skin*" J. Investigative Dermatology vol. 85, pp. 194-198 (1985).
Sharpe, et al., "Inhibition of Cutaneous Contact Hypersensitivity in the Mouse with Systemic or Topical Spiperone: Topical Application of Spiperone Produces Local Immunosuppression without Inducing Systemic Neuroleptic Effects" J. Investigative Dermatology vol. 99(5), pp. 594-600 (1992).
Sternberg, et al., "Effect of Serotonin on Murine Macrophages: Suppression of Ia Expression by Serotonin and its Reversal by 5-HT.sub.2 Serotonergic Receptor Antagonists" J. Immunology vol. 137(1), pp. 276-281 (1986) Fed. Proc. vol. 44(5), p. 7526 (1985).
Sternberg, et al., "Macrophage Activation by Serotonin (5-HT) is Affected by Interferon .gamma. (IFN.gamma.) Concentration and is antagonized by Spiperone and Ketanserin," Federation Proceedings, Abstracts, 44(5):7526 (1985).
Tucker, et al., "Inflammation in Acne Vulgaris: Leukocyte Attraction and Cytotoxicity by Comedonal Material" Investigative Dermatology vol. 74, pp. 21-25 (1980).
Reynolds, "Martindale, The Extra Pharmacopoeia," The Pharmaceutical Press, 1989.

Affiliated with

Also associated with

Rating

Use of spiperone derivatives as immunosuppressant agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of spiperone derivatives as immunosuppressant agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of spiperone derivatives as immunosuppressant agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-562812